CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to AMGN

6-Mercaptopurine

Phase 2
Amgen Inc. (AMGN)

Phase 2

Development Phase

0

Upcoming Catalysts

0

Historical Events

2

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Acute Lymphoblastic Leukemia

View Full Landscape
Drug Information

Target Indication

Acute Lymphoblastic Leukemia

Clinical Trial

NCT06533748

Last updated: 11/5/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals
EMAPending

Loulla

Treatment of acute lymphatic leukemia

Orphan
View on EMA
EMA3/9/2012

Xaluprine (previously Mercaptopurine Nova Laboratories)

Xaluprine is indicated for the treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children.

View on EMA
Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.